MX2014002214A - Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas. - Google Patents
Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas.Info
- Publication number
- MX2014002214A MX2014002214A MX2014002214A MX2014002214A MX2014002214A MX 2014002214 A MX2014002214 A MX 2014002214A MX 2014002214 A MX2014002214 A MX 2014002214A MX 2014002214 A MX2014002214 A MX 2014002214A MX 2014002214 A MX2014002214 A MX 2014002214A
- Authority
- MX
- Mexico
- Prior art keywords
- pacap
- vaccines
- adjuvant
- aquatic organisms
- molecular adjuvant
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 101150060255 MZB1 gene Proteins 0.000 title 1
- 101100462550 Mus musculus Adcyap1 gene Proteins 0.000 title 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 4
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 4
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000007598 dipping method Methods 0.000 abstract 1
- 244000078703 ectoparasite Species 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con el uso del péptido activador de la adenilato ciclasa de pituitaria (PACAP) como adyuvante molecular para vacunas; entre otras aplicaciones, dichas vacunas pueden emplearse en la protección contra agentes infecciosos, tales como virus, bacterias y ectoparásitos que afectan a los mamíferos, las aves y a los organismos acuáticos: el PACAP, combinado con un antígeno particular, demuestra su efectividad como adyuvante al aumentar la respuesta inmunológica del huésped contra dicho antígeno; este tipo de respuesta puede observarse cuando las composiciones o combinaciones vacunales que comprenden PACAP se administran por vía oral, inyección, o por baños de inmersión en el caso de los organismos acuáticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2011000167A CU24075B1 (es) | 2011-08-26 | 2011-08-26 | Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular. |
| PCT/CU2012/000004 WO2013029570A1 (es) | 2011-08-26 | 2012-08-24 | Uso del pacap como adyuvante molecular para vacunas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014002214A true MX2014002214A (es) | 2014-04-30 |
| MX351725B MX351725B (es) | 2017-10-25 |
Family
ID=47046313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002214A MX351725B (es) | 2011-08-26 | 2012-08-24 | Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9549977B2 (es) |
| EP (1) | EP2749291B1 (es) |
| JP (1) | JP6077541B2 (es) |
| KR (1) | KR101857705B1 (es) |
| CN (1) | CN103874510A (es) |
| AU (1) | AU2012303887B2 (es) |
| BR (1) | BR112014004620B1 (es) |
| CA (1) | CA2844898C (es) |
| CL (1) | CL2014000386A1 (es) |
| CU (1) | CU24075B1 (es) |
| ES (1) | ES2648337T3 (es) |
| MX (1) | MX351725B (es) |
| MY (1) | MY191697A (es) |
| NO (1) | NO2749291T3 (es) |
| PH (1) | PH12014500397B1 (es) |
| PT (1) | PT2749291T (es) |
| RU (1) | RU2580294C2 (es) |
| SG (1) | SG11201400215SA (es) |
| WO (1) | WO2013029570A1 (es) |
| ZA (1) | ZA201401271B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190060057A (ko) | 2017-11-24 | 2019-06-03 | 유병희 | 웰빙 무드등 |
| WO2020230869A1 (ja) * | 2019-05-14 | 2020-11-19 | 千寿製薬株式会社 | Ｐａｃａｐペプチド又はｐａｃａｐの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物 |
| CN117617183B (zh) * | 2023-11-29 | 2025-09-05 | 中国医学科学院医药生物技术研究所 | 突变体斑马鱼在制备凝血功能障碍疾病的动物模型中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE65568B1 (en) * | 1990-10-22 | 1995-11-01 | Unilever Plc | Vaccine compositions for fish |
| ES2307534T3 (es) * | 1999-09-28 | 2008-12-01 | Bayer Corporation | Agonistas de receptores 3 (r3) del peptido activador de la adenilato ciclasa hipofisiaria (pacap) y sus metodos de uso farmacologicos. |
| GB0427267D0 (en) * | 2004-12-13 | 2005-01-12 | Maria Teresa De Magistris | Peptide adjuvants |
| CU23557A1 (es) * | 2005-11-22 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Neuropéptidos para el cultivo de organismos acuáticos |
| AU2010313122A1 (en) * | 2009-11-02 | 2012-05-24 | The Administrators Of The Tulane Educational Fund | Analogs of pitutary adenylate cyclase-activating polypeptide (PACAP) and methods for their use |
| CN103255089B (zh) * | 2013-05-03 | 2015-08-05 | 中国水产科学研究院黄海水产研究所 | 一株强毒迟缓爱德华氏菌疫苗株及其应用 |
-
2011
- 2011-08-26 CU CU2011000167A patent/CU24075B1/es active IP Right Grant
-
2012
- 2012-08-24 JP JP2014526385A patent/JP6077541B2/ja active Active
- 2012-08-24 ES ES12775123.8T patent/ES2648337T3/es active Active
- 2012-08-24 KR KR1020147006186A patent/KR101857705B1/ko active Active
- 2012-08-24 CA CA2844898A patent/CA2844898C/en active Active
- 2012-08-24 CN CN201280041829.5A patent/CN103874510A/zh active Pending
- 2012-08-24 BR BR112014004620-4A patent/BR112014004620B1/pt active IP Right Grant
- 2012-08-24 MX MX2014002214A patent/MX351725B/es active IP Right Grant
- 2012-08-24 SG SG11201400215SA patent/SG11201400215SA/en unknown
- 2012-08-24 US US14/238,377 patent/US9549977B2/en active Active
- 2012-08-24 AU AU2012303887A patent/AU2012303887B2/en not_active Ceased
- 2012-08-24 MY MYPI2014700419A patent/MY191697A/en unknown
- 2012-08-24 EP EP12775123.8A patent/EP2749291B1/en active Active
- 2012-08-24 WO PCT/CU2012/000004 patent/WO2013029570A1/es not_active Ceased
- 2012-08-24 RU RU2014111465/15A patent/RU2580294C2/ru active
- 2012-08-24 PH PH1/2014/500397A patent/PH12014500397B1/en unknown
- 2012-08-24 PT PT127751238T patent/PT2749291T/pt unknown
- 2012-08-24 NO NO12775123A patent/NO2749291T3/no unknown
-
2014
- 2014-02-14 CL CL2014000386A patent/CL2014000386A1/es unknown
- 2014-02-19 ZA ZA2014/01271A patent/ZA201401271B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101857705B1 (ko) | 2018-06-20 |
| CL2014000386A1 (es) | 2014-07-11 |
| ZA201401271B (en) | 2015-04-29 |
| MY191697A (en) | 2022-07-07 |
| ES2648337T3 (es) | 2018-01-02 |
| EP2749291A1 (en) | 2014-07-02 |
| CU24075B1 (es) | 2015-01-29 |
| JP6077541B2 (ja) | 2017-02-08 |
| PH12014500397A1 (en) | 2014-04-14 |
| AU2012303887A1 (en) | 2014-03-06 |
| SG11201400215SA (en) | 2014-09-26 |
| US9549977B2 (en) | 2017-01-24 |
| EP2749291B1 (en) | 2017-10-18 |
| RU2014111465A (ru) | 2015-10-10 |
| CN103874510A (zh) | 2014-06-18 |
| NO2749291T3 (es) | 2018-03-17 |
| WO2013029570A1 (es) | 2013-03-07 |
| RU2580294C2 (ru) | 2016-04-10 |
| CU20110167A7 (es) | 2013-06-28 |
| CA2844898A1 (en) | 2013-03-07 |
| PT2749291T (pt) | 2017-11-24 |
| US20140294889A1 (en) | 2014-10-02 |
| JP2014524450A (ja) | 2014-09-22 |
| CA2844898C (en) | 2021-06-22 |
| PH12014500397B1 (en) | 2018-09-12 |
| BR112014004620B1 (pt) | 2019-10-29 |
| AU2012303887B2 (en) | 2017-06-22 |
| BR112014004620A2 (pt) | 2017-03-21 |
| KR20140064847A (ko) | 2014-05-28 |
| MX351725B (es) | 2017-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008303A (es) | Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika. | |
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| PH12015500092A1 (en) | Compositions for immunising against staphylococcus aureus | |
| BRPI0920240B8 (pt) | composição adjuvante | |
| CR20150170A (es) | Vacunas de inmersión subunidad para peces | |
| BR112016006192A2 (pt) | composição de vacina de divergente de pcv2b e métodos de uso | |
| EA201891124A3 (ru) | Новые мукозные адъюванты и системы доставки | |
| PH12014500385A1 (en) | Benzofuran compounds for the treatment of hepatitis c virus infections | |
| PH12015501378B1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
| WO2015144732A3 (en) | Uses of parasite macrophage migration inhibitory factors | |
| EA201491969A1 (ru) | Иммуногенные соединения, включающие пептид gp41 вич, связанный с белком-носителем crm197 | |
| MY167069A (en) | Antigen peptide and use thereof | |
| CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| MX2014002214A (es) | Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas. | |
| MX371126B (es) | Vacuna para cerdos contra el sindrome reproductivo y respiratorio porcino y lawsonia intracellularis. | |
| CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
| CL2014000760A1 (es) | Peptido antimicrobiano aislado y purificado de branquias de tilapia (oreochromis niloticus); acido nucleico que lo codifica; composicion que lo comprende; y su uso para el control de patogenos y como adyuvante molecular en una composicion vacunal para aumentar la respuesta inmune contra el antigeno vacunal. | |
| WO2015048785A3 (en) | Mosaic conserved region hiv immunogenic polypeptides | |
| EA201401044A1 (ru) | Модифицированный вирус болезни марека и вакцины на его основе | |
| CU24473B1 (es) | Composición vacunal que comprende un péptido secretagogo de la hormona de crecimiento como adyuvante vacunal | |
| TH151450A (th) | การใช้ของ pacap ในรูปโมเลกุลสารเสริมฤทธิ์สำหรับวัคซีน | |
| TH168553A (th) | องค์ประกอบของวัคซีนเด็งกี (dengue) ไวรัส | |
| TH159902A (th) | สารประกอบเบนโซฟิวแรนสำหรับรักษาการติดเชื้อไวรัสตับอักเสบ c | |
| TH172458A (th) | องค์ประกอบวัคซีนเพื่อการป้องกันต่อการติดเชื้อไวรัสเดงกี |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |